Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04702737 · ClinicalTrials.gov registry record · Phase 1
A Study of AMG 757 in Participants With Neuroendocrine Prostate Cancer
A Phase 1 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 1
- Development phase
- 41
- Enrollment target
NCT04702737 is a Phase 1 study that has completed, run by Amgen. The registered enrollment target is 41 participants.
The verdict
NCT04702737, a Phase 1 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 41 participants
- Enrollment target
Study Summary
To evaluate the safety and tolerability of Tarlatamab and will determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D).
Interventions
- DRUG Tarlatamab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2021-06-10 |
| Est. Completion | 2024-07-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04702737
The ClinicalTrials.gov registry entry for NCT04702737 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tarlatamab is the first listed.
NCT04702737 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04702737 about?
NCT04702737 is a clinical study titled "A Study of AMG 757 in Participants With Neuroendocrine Prostate Cancer". To evaluate the safety and tolerability of Tarlatamab and will determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D).
What is the current status of trial NCT04702737?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 41 participants. The study started on 2021-06-10. Estimated completion is 2024-07-22.
What interventions are being tested in trial NCT04702737?
The interventions under investigation include: Tarlatamab (DRUG).
Who is sponsoring clinical trial NCT04702737?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.